ISPE 2026: Real-world evidence of biosimilar uptake and switching in the US rituximab market

Authors: Vidya Venkataraman, PhD ⊕, Truveta, Inc, Bellevue, WA, Jared Kern ⊕, Truveta, Inc, Bellevue, WA, Joud Roufael, MPH ⊕, Truveta, Inc, Bellevue, WA, Puja Rao, MPH ⊕, Truveta, Inc, Bellevue, WA, Joseph Engeda, PhD ⊕, Truveta, Inc, Bellevue, WA, Esther Kim, PhD ⊕, Truveta, Inc, Bellevue, WA, Nadia Tabatabaeepour, MPH ⊕, Truveta, Inc, Bellevue, WA, Amy Sullivan, MS ⊕, Truveta, Inc, Bellevue, WA, Sarah Eng, MPH ⊕, Truveta, Inc, Bellevue, WA, Amy Wu ⊕ Truveta, Inc, Bellevue, WA, Biosimilar-only use increased from 56% of patients in 2021 to 75% in 2025, while Rituxan-only use declined from 37%